D. Boral Capital started coverage on shares of Plus Therapeutics (NASDAQ:PSTV – Free Report) in a report released on Monday morning, MarketBeat.com reports. The brokerage issued a buy rating and a $9.00 price target on the stock.
Other research analysts also recently issued research reports about the stock. Ascendiant Capital Markets dropped their price objective on shares of Plus Therapeutics from $20.00 to $19.00 and set a “buy” rating for the company in a research note on Monday, December 9th. HC Wainwright reissued a “buy” rating and set a $8.00 target price on shares of Plus Therapeutics in a research report on Tuesday, November 26th.
Read Our Latest Report on Plus Therapeutics
Plus Therapeutics Price Performance
About Plus Therapeutics
Plus Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.
Read More
- Five stocks we like better than Plus Therapeutics
- Investing in Construction Stocks
- Can TikTok Stock Picks Really Make You Rich?
- Biggest Stock Losers – Today’s Biggest Percentage Decliners
- The “Quality” Rotation: Back to Basics Investing
- What is a Death Cross in Stocks?
- Occidental Petroleum: 4 Reasons to Love These Prices
Receive News & Ratings for Plus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Plus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.